Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program. It also has a strategic collaboration with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-604-2957014
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$274,007.00
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
biOasis Technologies (CVE:BTI) Frequently Asked Questions
What is biOasis Technologies' stock symbol?
biOasis Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BTI."
How were biOasis Technologies' earnings last quarter?
When is biOasis Technologies' next earnings date?
Has biOasis Technologies been receiving favorable news coverage?
News stories about BTI stock have been trending positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. biOasis Technologies earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of biOasis Technologies' key competitors?
Some companies that are related to biOasis Technologies include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are biOasis Technologies' key executives?
biOasis Technologies' management team includes the folowing people:
- Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair (Age 61)
- Dr. Mark Day, Interim CFO, CEO, Pres, Chief Scientist & Director
- Ms. Catherine London, Exec. VP and Head of Corp. Communications & Investor Relations
- Mr. Kim Elton, Director of Marketing
- Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer
How do I buy shares of biOasis Technologies?
Shares of BTI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is biOasis Technologies' stock price today?
One share of BTI stock can currently be purchased for approximately C$0.46.
What is biOasis Technologies' official website?
How can I contact biOasis Technologies?
biOasis Technologies' mailing address is 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada. The company can be reached via phone at +1-604-2957014.
MarketBeat Community Rating for biOasis Technologies (CVE BTI)
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
